Skip to main content
Erschienen in: Tumor Biology 8/2016

21.03.2016 | Original Article

Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia

verfasst von: Qiuhua Zhu, Lingxiu Zhang, Xiaodong Li, Fang Chen, Ling Jiang, Guopan Yu, Zhixiang Wang, Changxin Yin, Xuejie Jiang, Qingxiu Zhong, Hongsheng Zhou, Bingjie Ding, Chunli Wang, Fanyi Meng

Erschienen in: Tumor Biology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Accumulating evidence indicates that enhancer of zeste homolog 2 (EZH2) promotes the metastatic ability of solid tumors, but the role of EZH2 in extramedullary infiltration (EMI) in acute myeloid leukemia (AML) has not been thoroughly explored. In the present study, we investigated the possible association between EZH2 and EMI. We found that the messenger RNA (mRNA) and protein expression levels of EZH2 in AML patients were both significantly higher than in idiopathic thrombocytopenic purpura (ITP) patients. Furthermore, a positive correlation between EZH2 mRNA expression and percentage of peripheral blood blasts wa s found in AML patients (r = 0.404, p = 0.009). The migratory capacities of Kasumi-1 and HL-60, which both show a high level of EZH2 expression, were markedly higher than those of U937 and KG-1α. In contrast, silencing of EZH2 resulted in reduction in proliferation and migration ability and an increase in apoptosis. The latter observation was accompanied by reduced expression of associated proteins p-ERK, p-cmyc, and matrix metalloproteinase 2 (MMP-2) and an increase in epithelial cadherin (E-cadherin). These data suggest that higher expression of EZH2 may be associated with extramedullary infiltration in acute myeloid leukemia and affect pathogenesis via activation of the p-ERK/p-cmyc/MMP-2 and E-cadherin signaling pathways.
Literatur
1.
Zurück zum Zitat Hiçsönmez G, Çetin M, Tuncer AM, Yenicesu İ, Aslan D, Özyürek E, et al. Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment. Leukemia Res. 2004;28:25–34.CrossRef Hiçsönmez G, Çetin M, Tuncer AM, Yenicesu İ, Aslan D, Özyürek E, et al. Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment. Leukemia Res. 2004;28:25–34.CrossRef
2.
Zurück zum Zitat Rege K, Swansbury GJ, Atra AA, Horton C, Min T, Dainton MG, et al. Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma. 2000;40:67–77.CrossRefPubMed Rege K, Swansbury GJ, Atra AA, Horton C, Min T, Dainton MG, et al. Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma. 2000;40:67–77.CrossRefPubMed
3.
Zurück zum Zitat Chang H, Brandwein J, Yi Q, Chun K, Patterson B, Brien B. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leukemia Res. 2004;28:1007–11.CrossRef Chang H, Brandwein J, Yi Q, Chun K, Patterson B, Brien B. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leukemia Res. 2004;28:1007–11.CrossRef
4.
Zurück zum Zitat Kobayashi R, Tawa A, Hanada R, Horibe K, Tsuchida M, Tsukimoto I. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia. Pediatr Blood Cancer. 2007;48:393–8.CrossRefPubMed Kobayashi R, Tawa A, Hanada R, Horibe K, Tsuchida M, Tsukimoto I. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia. Pediatr Blood Cancer. 2007;48:393–8.CrossRefPubMed
5.
Zurück zum Zitat Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997;15:466–75.CrossRefPubMed Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997;15:466–75.CrossRefPubMed
6.
Zurück zum Zitat Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, et al. EZH2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood. 2012;120:1107–17.CrossRefPubMed Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, et al. EZH2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood. 2012;120:1107–17.CrossRefPubMed
7.
Zurück zum Zitat Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039–43.CrossRefPubMed Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039–43.CrossRefPubMed
8.
Zurück zum Zitat Kim SH, Yang WI, Min YH, Ko YH, Yoon SO. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications. Tumor Biol. 2015. Kim SH, Yang WI, Min YH, Ko YH, Yoon SO. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications. Tumor Biol. 2015.
9.
Zurück zum Zitat Xiaojing Yang RKMK, Miller PBOT: CDKN1C(p57KIP2) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells Xiaojing Yang RKMK, Miller PBOT: CDKN1C(p57KIP2) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells
10.
Zurück zum Zitat Nakagawa S, Okabe H, Sakamoto Y, Hayashi H, Hashimoto D, Yokoyama N, et al. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Ann Surg Oncol. 2013;20:667–75.CrossRef Nakagawa S, Okabe H, Sakamoto Y, Hayashi H, Hashimoto D, Yokoyama N, et al. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Ann Surg Oncol. 2013;20:667–75.CrossRef
11.
Zurück zum Zitat Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, et al. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mutant p53. Cancer Lett. 2013;336:53–60.CrossRefPubMed Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, et al. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mutant p53. Cancer Lett. 2013;336:53–60.CrossRefPubMed
12.
Zurück zum Zitat Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, et al. Role of histone H3 lysine 27 methylation in X inactivation. Science. 2003;300:131–5.CrossRefPubMed Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, et al. Role of histone H3 lysine 27 methylation in X inactivation. Science. 2003;300:131–5.CrossRefPubMed
13.
Zurück zum Zitat Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol. 2001;112:950–8.CrossRefPubMed Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol. 2001;112:950–8.CrossRefPubMed
14.
Zurück zum Zitat Yamada A, Fujii S, Daiko H, Nishimura M, Chiba T, Ochiai A. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int J Oncol. 2011;38:345–53.PubMed Yamada A, Fujii S, Daiko H, Nishimura M, Chiba T, Ochiai A. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int J Oncol. 2011;38:345–53.PubMed
15.
Zurück zum Zitat Cao W, Ribeiro RO, Liu D, Saintigny P, Xia R, Xue Y, et al. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. Plos One. 2012;7:e52984.CrossRefPubMedPubMedCentral Cao W, Ribeiro RO, Liu D, Saintigny P, Xia R, Xue Y, et al. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. Plos One. 2012;7:e52984.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. Plos One. 2012;7:e33729.CrossRefPubMedPubMedCentral Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. Plos One. 2012;7:e33729.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling EZH2 expression and epigenetic reprogramming. Cancer Cell. 2013;23:768–83.CrossRefPubMed Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling EZH2 expression and epigenetic reprogramming. Cancer Cell. 2013;23:768–83.CrossRefPubMed
18.
Zurück zum Zitat Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y, et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol. 2011;90:643–53.CrossRefPubMed Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y, et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol. 2011;90:643–53.CrossRefPubMed
19.
Zurück zum Zitat Wu SH, Zheng CP, Xu J. A preliminary study on the relationship between EZH2 and microRNA-101 and the prognostic role of EZH2 in acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2012;33:232–5.PubMed Wu SH, Zheng CP, Xu J. A preliminary study on the relationship between EZH2 and microRNA-101 and the prognostic role of EZH2 in acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2012;33:232–5.PubMed
20.
Zurück zum Zitat Jiang L, Yu G, Meng W, Wang Z, Meng F, Ma W. Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2. Tumor Biol. 2013;34:629–36.CrossRef Jiang L, Yu G, Meng W, Wang Z, Meng F, Ma W. Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2. Tumor Biol. 2013;34:629–36.CrossRef
21.
Zurück zum Zitat Lin Y, Ren L, Xiong H, Du W, Yu Y, Sun T, et al. Role of STAT3 and vitamin D receptor inEZH2-mediated invasion of human colorectal cancer. J Pathol. 2013;230:277–90.CrossRefPubMed Lin Y, Ren L, Xiong H, Du W, Yu Y, Sun T, et al. Role of STAT3 and vitamin D receptor inEZH2-mediated invasion of human colorectal cancer. J Pathol. 2013;230:277–90.CrossRefPubMed
22.
Zurück zum Zitat Wang C, Chen Z, Li Z, Cen J. The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells. Leukemia Res. 2010;34:1083–90.CrossRef Wang C, Chen Z, Li Z, Cen J. The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells. Leukemia Res. 2010;34:1083–90.CrossRef
23.
Zurück zum Zitat Shin YJ, Kim J. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. Plos One. 2012;7:e30393.CrossRefPubMedPubMedCentral Shin YJ, Kim J. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. Plos One. 2012;7:e30393.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin a and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009;114:2733–43.CrossRefPubMedPubMedCentral Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin a and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009;114:2733–43.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, et al. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. 2015;117(2):351–62.CrossRefPubMed Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, et al. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. 2015;117(2):351–62.CrossRefPubMed
26.
Zurück zum Zitat Lee SCW, Phipson B, Hyland CD, Leong HS, Allan RS, Lun A, et al. Polycomb repressive complex 2 (PRC2) suppresses E-myc lymphoma. Blood. 2013;122:2654–63.CrossRefPubMed Lee SCW, Phipson B, Hyland CD, Leong HS, Allan RS, Lun A, et al. Polycomb repressive complex 2 (PRC2) suppresses E-myc lymphoma. Blood. 2013;122:2654–63.CrossRefPubMed
27.
Zurück zum Zitat Grubach L, Juhl-Christensen C, Rethmeier A, Olesen LH, Aggerholm A, Hokland P, et al. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol. 2008;81:112–22.CrossRefPubMed Grubach L, Juhl-Christensen C, Rethmeier A, Olesen LH, Aggerholm A, Hokland P, et al. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol. 2008;81:112–22.CrossRefPubMed
28.
Zurück zum Zitat Chen J, Li J, Han Q, Sun Z, Wang J, Wang S, et al. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia. Exp Biol Med. 2012;237:1110–6.CrossRef Chen J, Li J, Han Q, Sun Z, Wang J, Wang S, et al. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia. Exp Biol Med. 2012;237:1110–6.CrossRef
29.
Zurück zum Zitat Nishioka C, Ikezoe T, Yang J, Yokoyama A. Tetraspanin family member, CD82, regulates expression of EZH2 via inactivation of p38 MAPK signaling in leukemia cells. Plos One. 2015;10:e125017.CrossRef Nishioka C, Ikezoe T, Yang J, Yokoyama A. Tetraspanin family member, CD82, regulates expression of EZH2 via inactivation of p38 MAPK signaling in leukemia cells. Plos One. 2015;10:e125017.CrossRef
30.
Zurück zum Zitat Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011;118:2830–9.CrossRefPubMed Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011;118:2830–9.CrossRefPubMed
31.
Zurück zum Zitat Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther. 2006;5:3096–104.CrossRefPubMed Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther. 2006;5:3096–104.CrossRefPubMed
32.
Zurück zum Zitat Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 2004;18:1592–605.CrossRefPubMedPubMedCentral Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 2004;18:1592–605.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Janowska-Wieczorek A, Marquez LA, Matsuzaki A, Hashmi HR, Larratt LM, Boshkov LM, et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol. 1999;105:402–11.CrossRefPubMed Janowska-Wieczorek A, Marquez LA, Matsuzaki A, Hashmi HR, Larratt LM, Boshkov LM, et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol. 1999;105:402–11.CrossRefPubMed
34.
Zurück zum Zitat Yasuda T. MAP kinase cascades in antigen receptor signaling and physiology. Curr Top Microbiol Immunol. 2015;393:211–31. Yasuda T. MAP kinase cascades in antigen receptor signaling and physiology. Curr Top Microbiol Immunol. 2015;393:211–31.
Metadaten
Titel
Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia
verfasst von
Qiuhua Zhu
Lingxiu Zhang
Xiaodong Li
Fang Chen
Ling Jiang
Guopan Yu
Zhixiang Wang
Changxin Yin
Xuejie Jiang
Qingxiu Zhong
Hongsheng Zhou
Bingjie Ding
Chunli Wang
Fanyi Meng
Publikationsdatum
21.03.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 8/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4983-4

Weitere Artikel der Ausgabe 8/2016

Tumor Biology 8/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.